masthead-news

News & Events

HTG Molecular Diagnostics to Announce Third Quarter 2017 Financial Results and Host Conference Call on Tuesday, November 7

TUCSON, Ariz., Oct. 20, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that it will report its financial results for the three and nine months ended September 30, 2017 after the market close on Tuesday, November 7th. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.

Read More

Posted on:
 

HTG Molecular Diagnostics to Present at the Cantor Fitzgerald Global Healthcare Conference

TUCSON, Ariz., Sept. 25, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced its management will present a corporate overview at the Cantor Fitzgerald Global Healthcare Conference in New York City on Monday, September 25 at 9:45am Eastern Time.

Read More

Posted on:
 

HTG Molecular Diagnostics Receives ISO 13485 Certification for Health Canada CMDCAS Requirements

TUCSON, Ariz., Sept. 18, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that is has successfully completed an audit of its Quality Management System for continued certification to ISO 13485. This certification was issued by a registrar accredited under the Canadian Medical Device Conformity Assessment System (CMDCAS), which is required by Health Canada for the company to market in vitro diagnostic (IVD) products in Canada.

Read More

Posted on:
 

HTG Molecular Diagnostics Provides Regulatory Update for its HTG EdgeSeq ALKPlus Assay

TUCSON, Ariz., Sept. 11, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that it expects to complete and file the fourth and final module related to the premarket approval application (PMA) submission for its HTG EdgeSeq ALKPlus Assay in the second quarter of 2018. The first three modules of the PMA have already been submitted to the U.S. Food and Drug Administration (FDA) for review.

Read More

Posted on:
 

HTG Molecular Diagnostics to Present at the Rodman & Renshaw 19th Annual Investment Conference

TUCSON, Ariz., Sept. 06, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced its management will present at the Rodman and Renshaw 19th Annual Global Investment Conference in New York City on Monday, September 11, 2017, at 5:00 p.m. Eastern Time.

Read More

Posted on:
 

HTG Molecular Diagnostics’ Technology to be Used in WIN Consortium NSCLC Clinical Trial

TUCSON, Ariz., Aug. 09, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that its HTG EdgeSeq technology will be used together with Illumina next-generation sequencing (NGS) in a clinical trial conducted by the Worldwide Innovative Networking Consortium (WIN) investigating a novel therapeutic approach using a combination of three targeted therapies for the first line treatment of patients with advanced non-small cell lung cancer (NSCLC).

Read More

Posted on:
 

HTG Molecular Diagnostics Announces Second Companion Diagnostic Development Project with QIAGEN

TUCSON, Ariz. and VENLO, the Netherlands, July 27, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents and services for molecular profiling applications today announced the initiation of a second development program under the company’s Master Assay Development, Commercialization and Manufacturing Agreement (“Master Agreement”) with QIAGEN Manchester Limited, a wholly owned subsidiary of QIAGEN N.V. (NASDAQ:QGEN) (Frankfurt Stock Exchange:QIA) (“QIAGEN”). HTG EdgeSeq technology will be used in the program to develop gene expression profiling (“GEP”) assays for use with next-generation sequencing (“NGS”) technology in support of another pharmaceutical company’s therapeutic development and commercialization programs.

Read More

Posted on:
 

HTG Molecular Diagnostics to Hold 2017 Second Quarter Financial Results Conference Call on August 8, 2017

TUCSON, Ariz., July 18, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that the Company will release 2017 second quarter financial results after market close on Tuesday, August 8, 2017. Company management will host an investment-community conference call beginning at 4:30pm Eastern Time on Tuesday, August 8 to discuss these results and answer questions.

Read More

Posted on:
 

HTG Molecular Diagnostics Participating in WIN 2017 Symposium

TUCSON, Ariz., June 26, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced its participation in WIN 2017 Symposium, dedicated to Expediting Global Innovation in Precision Cancer Medicine, which is being held in Paris, France on June 26 and 27, 2017. HTG is an industry member of the Worldwide Innovative Networking (WIN) Consortium, whose mission is to rapidly translate personalized cancer medicine discoveries into standards of patient care worldwide. WIN is a non-profit global network of world-class academics, industries and patients’ advocates aiming to transform the practice of oncology and significantly improve survival and quality of life of cancer patients. HTG was actively recruited to the consortium to support gene expression profiling activities of its members, including WIN clinical trials that integrate RNA investigations in the clinical setting.

Read More

Posted on:

Page last updated September 29, 2020